<DOC>
	<DOCNO>NCT01020994</DOCNO>
	<brief_summary>The aim study determine efficacy safety topical application LAS41003 comparison LAS189962 LAS189961 treatment superinfect eczema .</brief_summary>
	<brief_title>Efficacy Safety LAS41003 Treatment Superficial Infected Eczema</brief_title>
	<detailed_description />
	<mesh_term>Eczema</mesh_term>
	<criteria>Clinically diagnose superinfect impetiginized eczema Patients general sign systemic infection like fever , malaise , lymphangitis swollen lymph node / need systemic antibiotic treatment Patients bacterial skin infection , due depth severity , could appropriately treated topical antimicrobial antiseptic medication Diagnose follow disease : Known active tuberculosis history past tuberculosis skin Suspected proven parasitic infection treatment site ( e.g . scabies ) Psoriasis Suspected proven viral infection skin ( e.g . Herpes ) Localization superficial infect eczema : Palms hand Sole foot Face Have receive topical treatment antibiotic , antimycotic , immunomodulators corticosteroid preparation within last 2 week treatment IMP</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2010</verification_date>
	<keyword>Superficial infect eczema</keyword>
	<keyword>Superinfected eczema</keyword>
</DOC>